Former BioClinica CEO Mark Weinstein to Join CRO Analytics Board of Directors
Weinstein Brings Two Decades of Pharma Software and Services Experience to Innovative Clinical Trial Quality Firm.
New Hope, PA, February 21, 2015 --(PR.com)-- CRO Analytics, the leading provider of clinical trial quality data and the only Clinical Trial Quality System (CTQS) in the clinical research market, announced former BioClinica President and CEO, Mark L. Weinstein has joined the CRO Analytics Board of Directors. This appointment follows the addition of Vance Kershner, CEO of LabWare, to the Board last month as a result of that LabWare’s Series A investment.
“To have someone with the experience and perspective that Mark brings is ideal,” said CEO and Board Chair, Peter Malamis. “He knows how to grow a company like ours, and most importantly, understands and supports CRO Analytics’ business model and strategy, knows our market, and fits our culture.”
Weinstein led BioClinica as the President and Chief Executive Officer for 16 years and has served as a Member of the Board of Directors since 1998. Under his leadership, BioClinica grew from under seven million dollars in revenue to over two hundred million. Prior to joining the then Bio-Imaging Technologies, Inc., he was the Chief Operating Officer of Internet Tradeline, Inc., an internet-based electronic solutions provider.
“It’s no secret that significant progress remains to be made in better understanding and subsequently improving overall clinical trial performance,” said Weinstein. “The core challenge is how to effectively introduce truly innovative solutions to an industry that has historically been hesitant to adopt change. I’m excited to be able to offer my learnings to CRO Analytics. I’m impressed with what they have done to date, especially with their CTQS, Performer™. I know they will make a real difference.”
“As leaders of the company, Mike (Dr. Mike Howley, co-founder and Chief Scientific Officer) and I are absolutely committed to surrounding ourselves with ‘A players’ from both an operating and Board perspective," said Malamis. “I want a board that’s going to challenge us to be better, not just be passive participants and after spending time with Mark I know that’s what we’re getting.”
Weinstein will replace original Board Member, Mike Wert. “I’d be remiss if I didn’t publicly offer our immense gratitude to Mike for all his advice, guidance, and support over the last four years,” Malamis added. “Mike is a true gentleman, a brilliant businessman, and a good friend. I told him he’s not completely off the hook. He still has to have lunch with me at least once a quarter.”
About CRO Analytics
Based in the Philadelphia region, CRO Analytics is the developer of PerformerTM, the only Clinical Trial Quality System (CTQS) in the clinical research industry and provider of related consulting services. The application is a cloud-based software platform designed to improve clinical research by assessing clinical trial quality. Data collected in a series of on-line instruments is analyzed using statistically validated algorithms to deliver actionable insights through standard and custom reports to clinical trial teams, functional area leads, and executives. The company launched Performer Version 1.0 earlier this year accompanied by the initial version of its Trial Management and Oversight module for Phase 2-4 clinical trials. To learn more, please visit croanalytics.com.
“To have someone with the experience and perspective that Mark brings is ideal,” said CEO and Board Chair, Peter Malamis. “He knows how to grow a company like ours, and most importantly, understands and supports CRO Analytics’ business model and strategy, knows our market, and fits our culture.”
Weinstein led BioClinica as the President and Chief Executive Officer for 16 years and has served as a Member of the Board of Directors since 1998. Under his leadership, BioClinica grew from under seven million dollars in revenue to over two hundred million. Prior to joining the then Bio-Imaging Technologies, Inc., he was the Chief Operating Officer of Internet Tradeline, Inc., an internet-based electronic solutions provider.
“It’s no secret that significant progress remains to be made in better understanding and subsequently improving overall clinical trial performance,” said Weinstein. “The core challenge is how to effectively introduce truly innovative solutions to an industry that has historically been hesitant to adopt change. I’m excited to be able to offer my learnings to CRO Analytics. I’m impressed with what they have done to date, especially with their CTQS, Performer™. I know they will make a real difference.”
“As leaders of the company, Mike (Dr. Mike Howley, co-founder and Chief Scientific Officer) and I are absolutely committed to surrounding ourselves with ‘A players’ from both an operating and Board perspective," said Malamis. “I want a board that’s going to challenge us to be better, not just be passive participants and after spending time with Mark I know that’s what we’re getting.”
Weinstein will replace original Board Member, Mike Wert. “I’d be remiss if I didn’t publicly offer our immense gratitude to Mike for all his advice, guidance, and support over the last four years,” Malamis added. “Mike is a true gentleman, a brilliant businessman, and a good friend. I told him he’s not completely off the hook. He still has to have lunch with me at least once a quarter.”
About CRO Analytics
Based in the Philadelphia region, CRO Analytics is the developer of PerformerTM, the only Clinical Trial Quality System (CTQS) in the clinical research industry and provider of related consulting services. The application is a cloud-based software platform designed to improve clinical research by assessing clinical trial quality. Data collected in a series of on-line instruments is analyzed using statistically validated algorithms to deliver actionable insights through standard and custom reports to clinical trial teams, functional area leads, and executives. The company launched Performer Version 1.0 earlier this year accompanied by the initial version of its Trial Management and Oversight module for Phase 2-4 clinical trials. To learn more, please visit croanalytics.com.
Contact
CRO Analytics
Margretta Feuer
215-230-9024
http://croanalytics.com
Margretta Feuer
215-230-9024
http://croanalytics.com
Contact
Categories